Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
AstraZeneca
Boehringer Ingelheim
RemeGen Co., Ltd.
Amgen
Merck Sharp & Dohme LLC
Angiochem Inc
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bristol-Myers Squibb
Takeda
Takeda
Pierre Fabre Medicament
Hoffmann-La Roche
AbbVie
Boehringer Ingelheim
Centocor, Inc.
Taiho Pharmaceutical Co., Ltd.
AstraZeneca
Sanofi